Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All patients age \> =18 who have been diagnosed with Multiple Myeloma and are scheduled for autologous peripheral blood hematopoietic stem cell transplant (AHSCT) will be screened for eligibility.~Patients must fulfill all of the following inclusion criteria to be eligible for this study:~1. Diagnosis of Multiple Myeloma~2. Age \>=18 and no more than 70 years.~3. Able to understand and sign a consent form.~4. Can collect peripheral blood stem cells with a CD34+ cell dose of at least 5.0 x 106/kg. The CD34 molecule is a Cluster of Differentiation molecule present on hematopoietic stem cells.~5. Conditioning regimen to be high dose Melphalan at a dose of 200mg/m2.~6. Karnofsky Performance Score (KPS) \>60 or ECOG (Eastern Cooperative Oncology Group) performance status \<=2~7. Kidney function:Creatinine \<2.0 mg/dl or creatinine clearance \>50 ml/min~8. Heart function: Ejection fraction \>45%~9. Liver function tests :Serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 3 X upper limit of normal~10. Lung function tests: Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second (FEV1) or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) \>45% predicted~Exclusion Criteria:~1. Age \<18 years or \> 70 years~2. Previous exposure to denileukin diftitox.~3. Patients with documented uncontrolled central nervous system (CNS) disease.~4. Previous AHSCT.~5. Significant organ dysfunction deemed to be inappropriate for autologous transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Denileukin Diftitox (Ontak) (Type: EXPERIMENTAL): Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).